Sign In
Buy PPBT
$1.40
+0.0300 (+2.19%)
At Close: Jul 31, 2026
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
07:00am, Friday, 30'th Aug 2024
REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ove
What Makes Purple Biotech (PPBT) a New Buy Stock
01:02pm, Wednesday, 21'st Aug 2024
Purple Biotech (PPBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights
08:12am, Friday, 16'th Aug 2024
Positive randomized Phase 2 CM24 pancreatic cancer study interim data presented at the American Society of Clinical Oncology ( ASCO) 2024 Annual Meeting demonstrates improvement in overall survival, p
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule
07:35am, Thursday, 25'th Jul 2024
REHOVOT, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
07:30am, Wednesday, 10'th Jul 2024
REHOVOT, Israel, July 10, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
04:00pm, Tuesday, 02'nd Jul 2024
REHOVOT, Israel, July 02, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies t
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
09:00am, Monday, 01'st Jul 2024
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
REHOVOT, Israel, June 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology th
REHOVOT, Israel, June 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies t
Purple Biotech Reports First Quarter 2024 Financial Results
07:30am, Tuesday, 21'st May 2024
CM24 Phase 2 Pancreatic Cancer Interim Data Selected for Late Breaking Abstract Poster Presentation at ASCO 2024 – Interim results to be Announced June 1, 2024 CM24 Phase 2 Pancreatic Cancer Interim
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
07:30am, Thursday, 14'th Mar 2024
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which incre
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher
10:56am, Wednesday, 13'th Mar 2024
Purple Biotech Ltd. Sponsored ADR (PPBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
11:52pm, Tuesday, 05'th Mar 2024
Purple Biotech (NASDAQ: PPBT ) just reported results for the fourth quarter of 2023. Purple Biotech reported earnings per share of -19 cents.
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
07:55am, Tuesday, 05'th Mar 2024
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harne
